$TORNTPHARM Q4 Profit Declines 26% Amid JB Pharma Integration and Restructuring Costs

$TORNTPHARM reported a 26% year-on-year decline in consolidated net profit for the fourth quarter of FY26, primarily due to one-time expenses associated with the acquisition and integration of JB Chemicals & Pharmaceuticals, along with employee severance payouts. Despite the drop in earnings, the company recorded a strong 42% rise in revenue following the consolidation of the newly acquired business. The Ahmedabad-headquartered drug maker, engaged in the generic formulations segment, posted a consolidated net profit of ₹364 crore for Q4 FY26, while revenue from operations increased to ₹4,197 crore. $TORNTPHARM s stated that quarterly profitability was affected by exceptional integration-related expenditures, including around ₹70 crore towards regulatory, compliance, and acquisition expenses, along with ₹19 crore paid as severance compensation related to the restructuring of JB Pharma’s distribution operations. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.